OC
TXMD icon

Oppenheimer & Co’s TherapeuticsMD TXMD Stock Holding History

Oppenheimer & Co’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-244
Closed -$4K – 1540
2022
Q1 		$4K Buy
+244
New +$3.84K ﹤0.01% 1463
2021
Q4 		– Sell
-383
Closed -$14K – 1574
2021
Q3 		$14K Sell
383
-382
-50% -$17K ﹤0.01% 1482
2021
Q2 		$46K Sell
765
-20
-3% -$1.21K ﹤0.01% 1489
2021
Q1 		$53K Sell
785
-500
-39% -$39.1K ﹤0.01% 1418
2020
Q4 		$77K Buy
1,285
+58
+5% +$3.96K ﹤0.01% 1317
2020
Q3 		$97K Buy
1,227
+248
+25% +$19.8K ﹤0.01% 1232
2020
Q2 		$61K Buy
979
+122
+14% +$7.1K ﹤0.01% 1229
2020
Q1 		$46K Sell
857
-115
-12% -$11.4K ﹤0.01% 1159
2019
Q4 		$118K Sell
972
-126
-11% -$18.1K ﹤0.01% 1235
2019
Q3 		$200K Sell
1,098
-873
-44% -$123K 0.01% 1145
2019
Q2 		$257K Buy
1,971
+1,110
+129% +$199K 0.01% 1070
2019
Q1 		$210K Sell
861
-407
-32% -$108K 0.01% 1200
2018
Q4 		$242K Sell
1,268
-27
-2% -$6.59K 0.01% 1034
2018
Q3 		$426K Buy
1,295
+118
+10% +$36.2K 0.01% 922
2018
Q2 		$366K Sell
1,177
-206
-15% -$62.9K 0.01% 987
2018
Q1 		$337K Sell
1,383
-152
-10% -$42.6K 0.01% 1002
2017
Q4 		$463K Buy
1,535
+49
+3% +$13.6K 0.01% 889
2017
Q3 		$393K Buy
1,486
+52
+4% +$15K 0.01% 938
2017
Q2 		$378K Buy
1,434
+605
+73% +$152K 0.01% 934
2017
Q1 		$298K Buy
829
+403
+95% +$125K 0.01% 1002
2016
Q4 		$123K Buy
+426
New +$132K ﹤0.01% 1219

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Oppenheimer & Co's TXMD Position: Q2 2022 in Review

Oppenheimer & Co sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 244 shares — an estimated $4K sold.

Oppenheimer & Co first reported a position in TXMD in Q4 2016 and held it in 21 quarters. The position peaked at $463K in Q4 2017. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Oppenheimer & Co reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Oppenheimer & Co sold 244 TherapeuticsMD shares in Q2 2022, an estimated $4K.
  • Oppenheimer & Co first reported a position in TherapeuticsMD in Q4 2016 and held it in 21 quarters.
  • Oppenheimer & Co's TherapeuticsMD position peaked at $463K in Q4 2017.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Oppenheimer & Co's 13F filing for Q2 2022, filed 8 Aug 2022.